A proprietary tomato extract – backed in EU health claim law to benefit blood circulation – has been shown to thin blood in healthy people – but less severely than aspirin and without typical side-effects.
Research has called into question the role of plant polyphenols in cardiovascular health, by finding that their supposed anti-platelet activities are only relevant at high, and physiologically unattainable, concentrations.
More than six months after receiving a positive health claim opinion from the European Food Safety Authority (EFSA) linking its tomato extract to blood circulation benefits, UK biotech firm Provexis has been handed final claim wording by the European...
A deal between Provexis and Coca-Cola over the use of its
tomato-based Fruitflow technology could be on the cards, according
to The Times, which may see heart health functional drinks
propelled into the mainstream.
Provexis has extended discussions over the use of its Fruitflow
tomato-based bioactive by a major global food company into 2007, as
it continues to tweak the technology platform to make it suitable
for a spectrum of food products.
The strategy of demonstrating the potential of new technology with
an own-brand launch in order to garner interest from major industry
players seems to be paying off for Provexis, which has progressed
with global licensing discussions...
UK firm Provexis looks set to release a novel heart-healthy drink
next year after recent human trials on its tomato-based product
proved successful. CardioFlow is a concentrated tomato extract but
it contains no lycopene.